Received systemic anticancer therapy or an investigational agent <2 weeks prior to Day 1 (washout from prior immune based anticancer therapy is 4 weeks). In addition, the first dose of study treatment should not occur before a period ?5 half-lives of the investigational agent has elapsed.Xx_NEWLINE_xXPrior anticancer therapy is allowed (excluding approved or investigational Trk, ROS1, or ALK inhibitors in patients who have tumors that harbor those respective gene rearrangements)Xx_NEWLINE_xXReceipt of systemic anticancer therapy, including investigational agents, within 5 times the agent's elimination half-life of starting study treatmentXx_NEWLINE_xXPatients may not be receiving other therapeutic investigational agents or be receiving concurrent anticancer therapy other than standard androgen deprivation therapy; concurrent treatment with agents to prevent skeletal-related events (such as zoledronic acid or denosumab) will be allowed as long as it was initiated prior to study entryXx_NEWLINE_xXPatients who have had systemic anticancer therapy (e.g., chemotherapy, targeted therapy) within 3 weeks prior to entering the studyXx_NEWLINE_xXOther anticancer agents and investigational agents should not be given while the subject is on study treatmentXx_NEWLINE_xXPatients must not have any anticancer therapy or investigational agent within 28 days prior to step 1 registrationXx_NEWLINE_xXPatients who are currently receiving other anticancer agentsXx_NEWLINE_xXAt least three weeks since last prior anticancer treatment and adequate recovery from prior treatment toxicityXx_NEWLINE_xXPrior anticancer systemic therapyXx_NEWLINE_xXConcurrent anticancer therapy (including other investigational agents) with the exception of hormone therapy for prostate cancer.Xx_NEWLINE_xXReceipt of any anticancer medication in the 21 days prior to receiving the first dose of study medicationXx_NEWLINE_xXAny chemotherapy, external beam radiation therapy, or anticancer antibodies within 2 weeksXx_NEWLINE_xXAble to discontinue all anticancer therapies 2 weeks prior to study startXx_NEWLINE_xXChemotherapy, immunotherapy or anticancer agents within 4 weeksXx_NEWLINE_xXReceipt of any other systemic anticancer therapy with the exception of hormonal therapy for a hormonally sensitive (e.g. breast or prostate) cancer (for treatment phase)Xx_NEWLINE_xXReceipt of any conventional or investigational anticancer therapy not otherwise specified within 21 days of the planned first dose.Xx_NEWLINE_xXPatients currently receiving anticancer therapies or who have received anticancer therapies within 2 weeks of the start of study drug (including chemotherapy, radiation therapy, and biologics). Patients who have received prior endocrine therapy for fertility purposes will be eligibleXx_NEWLINE_xXRadiotherapy - 2 weeks NOTE: Duration of any other anticancer therapies must be discussed with the Sponsor Study PhysicianXx_NEWLINE_xXUnresolved acute toxicity from prior anticancer therapyXx_NEWLINE_xXOngoing treatment with an anticancer agent.Xx_NEWLINE_xXSubjects previously treated with investigational anticancer therapies less than 6 weeks prior to the first dose of NivolumabXx_NEWLINE_xXOngoing treatment with an anticancer agent for MDS not contemplated in this protocol.Xx_NEWLINE_xXResearch participants receiving any other anticancer or investigational drug therapyXx_NEWLINE_xXSystemic therapy (standard or an investigational or biological anticancer agent)Xx_NEWLINE_xXPatients currently receiving anticancer therapies or who have received anticancer therapies within 2 weeks of the start of study drug (including chemotherapy, radiation therapy, and biologics)Xx_NEWLINE_xXTreatment with anticancer/investigational drugs, therapy ? 4 weeks prior to first dose of SC-002Xx_NEWLINE_xXOngoing treatment with an anticancer agent not contemplated in this protocol.Xx_NEWLINE_xXReceived systemic anticancer therapy within the previous 21 daysXx_NEWLINE_xXReceipt of any type of anticancer antibody (including investigational antibody) within 4 weeks before planned first dose of study drugXx_NEWLINE_xXSubjects currently receiving other anticancer therapies.Xx_NEWLINE_xXTreatment with any other anticancer therapy within 2 weeks of the start of study drug (i.e., other immunotherapy, chemotherapy, radiation therapy, etc.).Xx_NEWLINE_xXPrior or ongoing treatment with any of the following:\r\n* EGFR targeted therapy (TKI or antibody) or any other targeted therapies targeting the ERBB family\r\n* Any cytotoxic chemotherapy, investigational agents, or anticancer drugs for the treatment of advanced NSCLCXx_NEWLINE_xXReceipt of anticancer medications or investigational drugs within Protocol-defined time frames.Xx_NEWLINE_xXPrior or ongoing treatment with any of the following:\r\n* EGFR targeted therapy (TKI or antibody) or any other targeted therapies targeting the ERBB family\r\n* Any cytotoxic chemotherapy, investigational agents, or anticancer drugs for the treatment of metastatic NSCLCXx_NEWLINE_xXPatients receiving any other concurrent anticancer or investigational therapyXx_NEWLINE_xXReceived prior anticancer therapy within 21 days of first doseXx_NEWLINE_xXPatients receiving any other anticancer or investigational drug therapyXx_NEWLINE_xXAny cytotoxic chemotherapy, investigational agents, or anticancer drugs for advanced NSCLC used for a previous treatment regimen or clinical study within 14 days of the first dose of study treatment.Xx_NEWLINE_xXHas failed to recover from the reversible effects of prior anticancer therapyXx_NEWLINE_xXPatients who are actively receiving any other anticancer therapy except for hormonal therapy for well-controlled breast or prostate cancerXx_NEWLINE_xXPatients with solid tumors: Have received anticancer therapies, including radiation therapy, cytotoxic agents, targeted agents or endocrine therapy within 2 weeks prior to dose assignmentXx_NEWLINE_xXConcurrent anticancer therapy; however, radiotherapy is allowedXx_NEWLINE_xXCurrent or anticipated use of other investigational agents or marketed anticancer agent while on studyXx_NEWLINE_xXReceipt of anticancer medications or investigational drugs within the following intervals before the first administration of study drug:Xx_NEWLINE_xX?28 days for prior monoclonal antibody used for anticancer therapy with the exception of denosumab.Xx_NEWLINE_xXCytotoxic anticancer therapy (e.g., alkylating agents, anti-metabolites, purine analogues) or any other systemic anticancer therapy within 2 weeks of study entry.Xx_NEWLINE_xXThe patient has received treatment with chemotherapy, external-beam radiation, or other systemic anticancer therapy within 28 days prior to C1D1Xx_NEWLINE_xXThe patient has received treatment with an investigational systemic anticancer agent within 28 days prior to C1D1.Xx_NEWLINE_xXPatients who received any of the following within the 14 days before initiating study treatment: major surgery, radiation therapy, and/or systemic therapy (standard or an investigational or biological anticancer agent).Xx_NEWLINE_xXAt least three weeks since the last anticancer therapy, including investigational drugs and radiotherapy, and at least six weeks since nitrosoureas and mitomycin C(systemic).Xx_NEWLINE_xXTreatment with any anticancer therapyXx_NEWLINE_xXPatients will have recovered from toxicities from prior systemic anticancer treatment or local therapiesXx_NEWLINE_xXConcurrent therapy: no other concurrent anticancer or investigational therapy permitted except as noted aboveXx_NEWLINE_xXPatients must have recovered from toxicities from prior systemic anticancer treatment or local therapiesXx_NEWLINE_xXNo other concurrent anticancer therapy or prior prostate cancer vaccines expressing TARPXx_NEWLINE_xXFailed to recover from the reversible effects of prior anticancer therapies with the exception of alopeciaXx_NEWLINE_xXPatients currently receiving medical anticancer therapies or who have received medical anticancer therapies within 4 weeks of the start of study drug (including chemotherapy, antibody based therapy, etc.)Xx_NEWLINE_xXPatients currently receiving anticancer therapies or who have received anticancer therapies within 30 days of the start of study drug (including chemotherapy, radiation therapy, antibody based therapy, etc.); steroids for symptom palliation are allowed, but must be either discontinued or on stable doses at the time of initiation of protocol therapyXx_NEWLINE_xXAnticancer chemotherapy or immunotherapy during the study or within 5-halflives prior to start of study treatment. Mitomycin C, nitrosoureas or monoclonal antibodies with anticancer activity (e.g. bevacizumab or cetuximab etc.) should not be given within 6 weeks before starting to receive study treatment or within 6 weeks of pre-treatment biopsy for biomarker (p-ERK1/2) studiesXx_NEWLINE_xXPatients who have received the last administration of an anticancer therapy including chemotherapy, immunotherapy, and monoclonal antibodies =< 4 weeks prior to starting study drug, or who have not recovered from the side effects of such therapyXx_NEWLINE_xXReceived any other investigational therapeutic agents or other anticancer therapies within 4 weeks prior to randomizationXx_NEWLINE_xXRelapsed or refractory hematologic malignancy (lymphoma or multiple myeloma) that has progressed, or is currently progressing with standard anticancer therapy or for which no other approved therapy exist. Lymphoma patients must have failed at least 2 standard anticancer therapies, and multiple myeloma patients must have failed at least 3 standard anticancer therapies.Xx_NEWLINE_xXAny prior anticancer therapy for esophageal cancerXx_NEWLINE_xXParticipants must not have had prior systemic anticancer therapy for unresectable or metastatic melanomaXx_NEWLINE_xXPatients who received any systemic anticancer therapy within 2 weeks before randomization.Xx_NEWLINE_xXCytotoxic chemotherapy, investigational agents, or any anticancer therapy for the treatment of advanced NSCLC (other than EGFR TKI) within 21 days of the first dose of study treatmentXx_NEWLINE_xXAny cytotoxic chemotherapy or other anticancer drugs from previous treatment regimen or clinical study within 14 days of first dose of study drugXx_NEWLINE_xXSTRATUM A: Participants must have received their last dose of anticancer therapy (including experimental) at least 4 weeks prior to study enrollmentXx_NEWLINE_xXSTRATUM B: Participants must have received their last dose of anticancer therapy (including experimental) at least 4 weeks prior to study enrollmentXx_NEWLINE_xXSTRATUM C: Participants must have received their last dose of anticancer therapy (including experimental) at least 4 weeks prior to study enrollmentXx_NEWLINE_xXImmunotherapy and/or investigational anticancer therapy with agents including mAbs : ?4 weeksXx_NEWLINE_xXHas unresolved toxicities from previous anticancer therapyXx_NEWLINE_xXConcurrent anticancer therapy (including other investigational agents) with the exception of hormone therapy for breast or prostate cancer; patients that have received treatment for a different cancer previously and have been disease-free for less than one year are excludedXx_NEWLINE_xXChemotherapy, small molecule inhibitors, radiation, and/or other investigational anticancer agents (excluding investigational monoclonal antibodies): 2 weeks.Xx_NEWLINE_xXLast dose of anticancer therapy must have been administered within 6 months of the date of randomization into this study.Xx_NEWLINE_xXLast dose of anticancer therapy (including HER2-targeted therapy) within 14 days prior to randomization.Xx_NEWLINE_xXConcomitant use of any anticancer therapy or use of any investigational agent(s).Xx_NEWLINE_xXPatients receiving any other anticancer or experimental drug therapyXx_NEWLINE_xXConcurrent use of other anticancer agents including chemotherapy, targeted therapy, radiotherapy or immunotherapy not otherwise specified in the protocolXx_NEWLINE_xXAnticancer therapy, including but not limited to chemotherapy, hormonal therapy, or radiotherapy, within 4 weeks prior to start of study treatment; however, the following are allowed:\r\n* Hormone-replacement therapy or oral contraceptives.\r\n* Herbal therapy > 1 week prior to start of study treatment (herbal therapy intended as anticancer therapy must be discontinued at least 1 week prior to start of study treatment).\r\n* Palliative radiotherapy for bone metastases > 2 weeks prior to start of study treatment.Xx_NEWLINE_xXExpected to require any other form of systemic or localized anticancer therapy while on study.Xx_NEWLINE_xXIntolerance to immune checkpoint inhibitor therapy as defined by the occurrence of an adverse drug reaction requiring drug discontinuation (dose escalation cohorts), concurrent anticancer treatment or immunosuppressive agents.Xx_NEWLINE_xXHave received no prior lines of systemic therapy and are suitable to receive doxorubicin, ifosfamide and mesna. All previous anticancer treatments must have completed ?3 weeks (21 days) prior to the first dose of study treatment.Xx_NEWLINE_xXReceiving any anticancer therapy for biliary tract cancer =< 21 days prior to registrationXx_NEWLINE_xXPatients currently receiving anticancer therapies or who have received anticancer therapies (including chemotherapy and targeted therapy) within 2 weeks (14 days) prior to study day are excluded. Patients who have completed palliative radiation therapy more than 14 days prior to the first dose of the combination ipilimumab plus nivolumab are eligible.Xx_NEWLINE_xXTreatment with prohibited medications (including concurrent anticancer therapy including chemotherapy, radiation, hormonal treatment [except corticosteroids and megestrol acetate]) =< 14 days prior to treatmentXx_NEWLINE_xXPrior systemic, regional and radiation anticancer therapies must have been completed at least three months prior to enrollment; prior therapies (including anti-PD-1 inhibitors) is allowed provided three months have elapsed from last doseXx_NEWLINE_xXThe subject has a diagnosis of another malignancy within 2 years before the first dose of study treatment, except for superficial skin cancer, localized prostate cancer on active surveillance, or localized solid tumors deemed cured by surgery and not treated with systemic anticancer therapy and not expected to require anticancer therapy in the next 2 years i.e., while the subject may be taking study treatmentXx_NEWLINE_xXAny cytotoxic chemotherapy, immune checkpoint inhibitor therapy, investigational agent or other anticancer drug(s) from a previous cancer treatment regimen or clinical study (other than EGFR TKI), within 14 days of the first dose of study treatment.Xx_NEWLINE_xXParticipants who are currently receiving other anticancer agents.Xx_NEWLINE_xXConcurrent therapy with approved or investigational anticancer therapeutics.Xx_NEWLINE_xXNo concurrent therapy with approved or investigational anticancer therapeuticsXx_NEWLINE_xXReceipt of systemic anticancer therapy, including investigational agents, within 28 days prior to study treatment (Note: If anticancer therapy was given within 28 days prior to starting study treatment, patients are not excluded if ? 5 times the elimination half-life of the drug has elapsed.)Xx_NEWLINE_xXPrior or concurrent treatment with any anticancer agent for the same cancer diagnosisXx_NEWLINE_xXPatients who are actively receiving any other anticancer therapyXx_NEWLINE_xXAny concurrent anticancer therapyXx_NEWLINE_xXFewer than 28 days from prior anticancer therapy including chemotherapy, hormonal, investigational, and/or biological therapies and irradiation except for:Xx_NEWLINE_xXUse of any other concurrent investigational agents or anticancer agents including hormonal therapy, except in the case of prostate cancer patients who are being treated anti-androgen or bone targeting therapies.Xx_NEWLINE_xXAny prior anticancer therapy for this diagnosisXx_NEWLINE_xXHave received or are receiving an investigational medicinal product (IMP) or other systemic anticancer treatment within 2 weeks prior to the first dose of study treatmentXx_NEWLINE_xXPatients who are receiving any other anticancer agents.Xx_NEWLINE_xXMCL requiring treatment and for which no prior systemic anticancer therapies have been received.Xx_NEWLINE_xXPatients currently receiving anticancer therapies or who have received anticancer therapies within 2 weeks (14 days) from enrollment into this study (including chemotherapy and targeted therapy) are excluded; also, patients who have completed palliative radiation therapy more than 14 days prior to the first dose of MGCD516 are eligibleXx_NEWLINE_xXReceipt of anticancer chemotherapy within 4 weeks before the administration of study drugXx_NEWLINE_xXReceipt of anticancer chemotherapy within 4 weeks before the first administration of study drugXx_NEWLINE_xXConcurrent treatment with any other anticancer therapyXx_NEWLINE_xXConcurrent use of conventional or investigational anticancer agents, except hydroxyureaXx_NEWLINE_xXUse of other systemic anticancer treatments or agents within the past 2 weeks (4 weeks if the therapy was a monoclonal antibody)Xx_NEWLINE_xXPatients who are receiving any other anticancer therapyXx_NEWLINE_xXAny anticancer therapy or investigational agent within prior 3 weeks.Xx_NEWLINE_xXSystemic anticancer therapy within 21 days of the first dose of study drug\r\n* All adverse events from prior systemic therapy must have either stabilized or returned to baselineXx_NEWLINE_xXAny investigational anticancer therapy received within 28 days prior to the first dose of durvalumab and tremelimumabXx_NEWLINE_xXAnticipated need for concomitant administration of any other experimental drug, or a concomitant chemotherapy, anticancer hormonal therapy, radiotherapy, or immunotherapy during study participation.Xx_NEWLINE_xXConcomitant therapy with any other anticancer therapy or chronic use of systemic corticosteroids.Xx_NEWLINE_xXConcurrent anticancer therapy (including other investigational agents)Xx_NEWLINE_xXRecurrent or progressive malignancy requiring anticancer treatmentXx_NEWLINE_xXUse of any other concurrent investigational agents or anticancer agents including hormonal therapy, except in the case of prostate cancer patients who are being treated with LHRH agonist at the time of trial entryXx_NEWLINE_xXAnticancer therapy within 2 weeks prior to initiating study treatmentXx_NEWLINE_xXPlans for concurrent anticancer therapy except as permittedXx_NEWLINE_xXUnresolved toxicity from previous anticancer therapy or incomplete recovery from surgeryXx_NEWLINE_xXCompletion of prior chemotherapy systemic anticancer therapy at least 2 weeks prior to study entryXx_NEWLINE_xXPatients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of the investigational therapy (including chemotherapy, radiation therapy, antibody based therapy)Xx_NEWLINE_xXAny prior anticancer therapyXx_NEWLINE_xXNo previous anticancer therapy (radiation therapy or chemotherapy) other than use of corticosteroidsXx_NEWLINE_xXNo previous anticancer therapy (radiation therapy or chemotherapy) other than the use of corticosteroidsXx_NEWLINE_xXPatients may not be receiving other investigational agents or be receiving concurrent anticancer therapy other than standard androgen deprivation therapyXx_NEWLINE_xXReceipt of a small molecule anticancer agent, including an investigational anticancer small molecule, within 14 days of starting study treatmentXx_NEWLINE_xXReceipt of a large molecule anticancer agent (e.g., antibody), including an investigational anticancer antibody, within 28 days of starting study treatmentXx_NEWLINE_xXConcurrent use of other anticancer approved or investigational agents is not allowed.Xx_NEWLINE_xXPatient is receiving concomitant standard and/or investigational anticancer therapy; local palliative radiotherapy is permissible upon discussion with the principal investigatorXx_NEWLINE_xXPatients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks including chemotherapy, radiation therapy, antibody based therapy, etc.Xx_NEWLINE_xXConcurrent therapy with approved or investigational anticancer therapyXx_NEWLINE_xXNo concurrent anticancer chemotherapy or local therapyXx_NEWLINE_xXAnticancer therapy, monoclonal antibody or major surgery within 4 weeks prior to the first dose of MEDI4736\r\n* Concurrent use of hormones for non-cancer-related conditions (e.g., insulin for diabetes and hormone replacement therapy) is acceptableXx_NEWLINE_xXUse of investigational agents within 30 days or any anticancer therapy within 2 weeks prior to entering this study with the exception of hydroxyurea; the patient must have recovered from all acute toxicities from any previous therapyXx_NEWLINE_xXTreatment for malignancy with anticancer therapy, including cytotoxic agents, hormonal agents, or immunotherapy, within 5 years of enrollmentXx_NEWLINE_xXNo other concurrent anticancer therapyXx_NEWLINE_xXImmunotherapy or chemotherapy with approved or investigational anticancer therapeutics within 4 weeks of first doseXx_NEWLINE_xXUse of other anticancer treatments or agents within the past 4 weeks (6 weeks if the therapy was a monoclonal antibody)Xx_NEWLINE_xXPatients who are receiving any other anticancer or investigational drug therapy are not eligibleXx_NEWLINE_xXReceipt of anticancer medications, anticancer therapies, or investigational drugs within the defined interval before the first administration of study drug.Xx_NEWLINE_xXReceipt of anticancer medications or investigational drugs within a defined interval before the first administration of study drug.Xx_NEWLINE_xXPrior chemotherapy, small molecule inhibitors, and/or other investigational anticancer agents (excluding investigational monoclonal antibodies) within 4 weeksXx_NEWLINE_xXPatients receiving any other anticancer or experimental drug therapyXx_NEWLINE_xXPatients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of study drug (including chemotherapy, antibody based therapy, e.g. lapatinib, bevacizumab, erlotinib, imatinib, that are sometimes offered on a compassionate-use basis to NF2 patients)Xx_NEWLINE_xXRequirement for other forms of anticancer treatment while on trial, including maintenance therapy, other radiation therapy, and/or surgery.Xx_NEWLINE_xXAnticancer Agents: participants who are currently receiving other anticancer agentsXx_NEWLINE_xXUnresolved toxicities from previous anticancer therapy.Xx_NEWLINE_xXAny systemic anticancer therapy within 3 weeks of the first dose of study treatment. For cytotoxic agents that have major delayed toxicity, e.g. mitomycin C and nitrosoureas, or anticancer immunotherapies, a washout period of 6 weeks is required. For patients in Cohort 2, this does not apply to the most recently received hormone therapy.Xx_NEWLINE_xXConcurrent anticancer treatment within 28 days before the start of trial treatmentXx_NEWLINE_xXReceipt of any systemic anticancer therapy within 28 days prior to the first dose of MEDI5083Xx_NEWLINE_xX?3 weeks for local radiation therapy, systemic cytotoxic anticancer therapy, treatment with other anti-neoplastic investigational agentsXx_NEWLINE_xXConcurrent therapy with approved or investigational anticancer therapeutic other than steroidsXx_NEWLINE_xXReceived prior systemic anticancer treatment (chemotherapy, targeted therapies including kinase inhibitors, antibodies, etc) less than 5 half-lives before the first dose of study drug or radiotherapy within 30 days; toxicity of the anticancer treatment must have recovered to grade 1 or less.Xx_NEWLINE_xXNeed for other anticancer treatmentXx_NEWLINE_xXConcurrent treatment with any other anticancer therapyXx_NEWLINE_xXReceipt of anticancer medications, anticancer therapies, or investigational drugs within protocol-defined intervals before the first administration of study drug.Xx_NEWLINE_xXReceipt of any vitamin K antagonists, systemic corticosteroids, live vaccines, or treatment with any anticancer medications or investigational drugs within the protocol-defined intervals.Xx_NEWLINE_xXHas received prior anticancer therapy including investigational agents within 4 weeks prior to randomizationXx_NEWLINE_xXAnticancer therapy within 14 days of first G1T48 dose or within 28 days for antibody-based therapyXx_NEWLINE_xXPrior anticancer therapy is allowed, including prior checkpoint inhibitor treatment.Xx_NEWLINE_xXAnticancer treatment (chemotherapy, IMiD, PI, molecular targeted therapy) < 2 weeks prior to study Day 1Xx_NEWLINE_xXConcurrent use of other anticancer approved or investigational agents is not allowed.Xx_NEWLINE_xXTreatment with prior chemotherapy, monoclonal antibodies, other protein or peptide therapeutics or anticancer immunotherapy within 21 days of the first dose of study drugXx_NEWLINE_xXHistory of prior treatment with at least one line of systemic anticancer therapy, when an approved systemic therapy is available, and no curative option is available for continued treatmentXx_NEWLINE_xXUse of investigational agents within 30 days or any anticancer therapy for this malignancy within 2 weeks before study entry with the exception of intrathecal (IT) therapy, hydroxyurea, or low-dose cytarabine as stated above; the patient must have recovered from all acute toxicities from any previous therapyXx_NEWLINE_xXConcurrent treatment with other experimental drugs or any other systemic anticancer therapy (due to unknown drug-vaccine potential interactions)Xx_NEWLINE_xXInvestigational agent, anticancer therapy, or major surgery within 14 days (2 weeks) prior to C1D1Xx_NEWLINE_xXAny non-investigational anticancer therapy within prior 2 weeksXx_NEWLINE_xXConcomitant therapy with any anticancer agents, immunosuppressive agents, other investigational anticancer therapiesXx_NEWLINE_xXPatients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of study drug (including chemotherapy, radiation therapy, antibody based therapy, etc.)Xx_NEWLINE_xXNot currently receiving any anticancer therapyXx_NEWLINE_xXChemotherapy, small molecule inhibitors, radiation, and/or other investigational anticancer agents (excluding investigational monoclonal antibodies): 2 weeksXx_NEWLINE_xXThe subject has a diagnosis of another malignancy within 2 years before the first dose of study treatment, except for superficial skin cancer or localized solid tumors deemed cured by surgery and not treated with systemic anticancer therapy and not expected to require anticancer therapy in the next 2 years i.e., while the subject may be taking study treatment. However, subjects with low-risk prostate cancer, e.g.:Xx_NEWLINE_xXNo other current active malignancy requiring anticancer therapy.Xx_NEWLINE_xXReceipt of anticancer medications or investigational drugs within protocol-specified intervalsXx_NEWLINE_xXOngoing acute adverse effects from prior anticancer or investigational therapy > NCI CTCAE Grade 1Xx_NEWLINE_xXRadiation or anti-hormonal therapy or other targeted anticancer therapy within 14 days before randomizationXx_NEWLINE_xXA minimum of 1 week since the last dose of prior therapy (a minimum of 4 weeks since anticancer immune therapy or bevacizumab +/- interferon).Xx_NEWLINE_xXPatients currently receiving non-hormonal anticancer therapies or who have received non-hormonal anticancer therapies within 4 weeks from day 1 of study drug (including investigational agents, chemotherapy, radiation therapy, antibody based therapy, etc.); if radiation was received exclusively for bony metastases and the interval between completion of radiation treatments and the first infusion of study drug is less than 7 days; hormonal therapies are not excludedXx_NEWLINE_xXConcurrent anticancer treatment or immunosuppressive agentsXx_NEWLINE_xXPatients who received systemic anticancer therapy or radiotherapy <21 days prior to their first day of study drug administrationXx_NEWLINE_xXAny approved anticancer therapy, including chemotherapy, or hormonal therapy (except hormone-replacement therapy or oral contraceptives) within 3 weeks of first dose.Xx_NEWLINE_xXAny type of anticancer agent (including investigational) within 2 weeks before randomization.Xx_NEWLINE_xXReceived any chemotherapy, external beam radiation therapy, anticancer antibodies, or investigational drug within 30 days before first dose of study drug.Xx_NEWLINE_xXPrior anticancer treatments or therapies within the indicated time window prior to first dose of study treatment (ASTX660), as follows:Xx_NEWLINE_xXPatients who are receiving any other investigational agents or anticancer therapy concurrently or within 4 weeks (ie 28 days)Xx_NEWLINE_xXAny other chemotherapy, immunotherapy or anticancer agents within 2 weeks of the first dose of study treatment.Xx_NEWLINE_xXReceipt of anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug.Xx_NEWLINE_xXConcomitant use of any other investigational or anticancer agent(s).Xx_NEWLINE_xXReceipt of a small molecule anticancer agent, including an investigational anticancer small molecule, within 14 days of starting study treatmentXx_NEWLINE_xXReceipt of systemic anticancer therapy, including investigational agents, within 28 days of starting study treatment. If anticancer therapy was given within 28 days of starting study treatment, patients may be included if 5 times the elimination half-life of the drug has passed. a biologic anticancer agent (e.g., antibody), including an investigational anticancer antibody, within 28 days of starting study treatmentXx_NEWLINE_xXReceipt of anticancer medications or investigational drugs within a defined interval before the first administration of study drug.Xx_NEWLINE_xXCompletion of all prior anticancer therapy before first ACP-196 dose.Xx_NEWLINE_xXUnresolved toxicities from prior anticancer therapyXx_NEWLINE_xXReceived any anticancer medication or therapy in the 21 days prior to study Day 1Xx_NEWLINE_xXHas had certain other recent treatment e.g. major surgery, anticancer therapy, extended field radiation, received investigational agent within the specified time frames prior to study drug administration.Xx_NEWLINE_xXUnresolved toxicities from previous anticancer therapyXx_NEWLINE_xXSystemic treatment with anticancer therapy within 3 weeks before study drug treatmentXx_NEWLINE_xXPrior systemic, regional and radiation anticancer therapies for melanoma must have been completed at least 3 months prior to randomization.Xx_NEWLINE_xXTreatment with systemic anticancer therapy for CLL is prohibited between discontinuation of ibrutinib and enrollment on this trial.Xx_NEWLINE_xXTreatment-naïve participants (no prior systemic anticancer therapy for unresectable or metastatic melanoma)Xx_NEWLINE_xXSUB-PROTOCOL AIM A: Concurrent use of any other approved or investigational anticancer agents which would be considered as a treatment for the primary neoplasmXx_NEWLINE_xXnot discontinued CD20-targeted therapy, chemotherapy, radiotherapy, investigational anticancer therapy or other lymphoma specific therapyXx_NEWLINE_xXconcurrently use other anticancer or experimental treatmentsXx_NEWLINE_xXInclusion Criteria: - Age ?18 years; - Written informed consent obtained from the\n        patient/legal representative; - Histologically or cytologically confirmed recurrent or\n        metastatic SCCHN; - Tumor progression or recurrence during or after only one palliative\n        systemic treatment regimen for recurrent or metastatic disease that must have contained a\n        platinum agent OR progression within 6 months of the last dose of platinum given as part of\n        multimodality therapy with curative intent; - Confirmed PD-L1-positive or -negative SCCHN\n        by the Ventana PD-L1 SP263 IHC assay; - WHO/Eastern Cooperative Oncology Group (ECOG)\n        performance status of 0 or 1; At least 1 measurable lesion, - Not previously irradiated; -\n        No prior exposure to immune-mediated therapy; - Adequate organ and marrow function;\n        Evidence of post-menopausal status or negative urinary or serum pregnancy test for female\n        pre-menopausal patients. Exclusion Criteria: - Histologically or cytologically confirmed\n        squamous cell carcinoma of any other primary anatomic location in the head and neck; -\n        Received more than 1 palliative systemic regimen for recurrent or metastatic disease; -Any\n        concurrent chemotherapy, Investigational Product, biologic, or hormonal therapy for cancer\n        treatment; - Receipt of any investigational anticancer therapy within 28 days or 5\n        half-lives; - Receipt of last dose of an approved (marketed) anticancer therapy\n        (chemotherapy, targeted therapy, biologic therapy, mAbs, etc) within 21 days prior to the\n        first dose of study treatment; - Major surgical procedure within 28 days prior to the first\n        dose of Investigational Product; - Any unresolved toxicity NCI CTCAE Grade ?2 from previous\n        anticancer therapy with the exception of alopecia, vitiligo, and the laboratory values\n        defined in the inclusion criterion; - Current or prior use of immunosuppressive medication\n        within 14 days before the first dose of their assigned Investigational Product; - History\n        of allogeneic organ transplantation; - Active or prior documented autoimmune or\n        inflammatory disorders; - Uncontrolled intercurrent illness; - Patients with a history of\n        brain metastases, spinal cord compression, or leptomeningeal carcinomatosis; - Mean QT\n        interval corrected for heart rate (QTc) ?470 ms calculated from 3 electrocardiograms (ECGs)\n        using Fridericia's Correction; - History of active primary immunodeficiency; - Active\n        tuberculosis; - Active infection including hepatitis B, hepatitis C or human\n        immunodeficiency virus (HIV); - Receipt of live, attenuated vaccine within 30 days prior to\n        the first dose of Investigational Product; - Pregnant or breast-feeding female patients; -\n        Known allergy or hypersensitivity to Investigational ProductXx_NEWLINE_xXReceipt of a small molecule anticancer agent, including an investigational anticancer small molecule, within 14 days of starting study treatment or receipt of a biologic anticancer agent (e.g., antibody) within 28 days of starting study treatment.Xx_NEWLINE_xXUse of investigational agents within 2 weeks or any anticancer therapy within 2 weeks before study entry; the patient must have recovered from all acute toxicities from any previous therapyXx_NEWLINE_xXSubjects who have progressed on (or not been able to tolerate) standard anticancer therapy or for whom no standard anticancer therapy exists. Must have disease that is objectively measurableXx_NEWLINE_xXPrevious treatment with > 2 anticancer regimens for ovarian cancerXx_NEWLINE_xXSubject has not been treated by systemic anticancer therapy for unresectable or metastatic melanomaXx_NEWLINE_xXParticipants who have received any anticancer treatment within 3 weeks or any investigational agent within 30 days before the first dose of study drug or who have not recovered from any acute toxicity greater than Grade 0 or 1 related to previous anticancer treatment.Xx_NEWLINE_xXReceipt of anticancer therapy:Xx_NEWLINE_xXPrior anticancer or investigational drug treatment within the following windows:Xx_NEWLINE_xXCurrent or recent treatment with biologic anticancer therapiesXx_NEWLINE_xXOngoing AEs from prior anticancer therapiesXx_NEWLINE_xXSystemic anticancer therapy (chemotherapy, “biologics”, immunotherapy) less than two weeks prior to starting radiationXx_NEWLINE_xXPatients currently receiving anticancer therapies or who have received anticancer therapies within 28 days from day 1 of study drug (including investigational agents, chemotherapy, radiation therapy, antibody based therapy, etc.); if radiation was received for bone metastases (palliative radiation), the minimum interval between completion of radiation treatment and first dose of study drug is 14 daysXx_NEWLINE_xXAny ongoing acute clinically significant toxic effect of prior anticancer therapy or any persisting complication of prior surgery.Xx_NEWLINE_xXHas had certain other recent treatment e.g. major surgery, anticancer therapy, extended field radiation, received investigational agent, within the specified time frames prior to study drug administration.Xx_NEWLINE_xXConcurrent therapy with any other investigational anticancer agentXx_NEWLINE_xXPhase1: Treatment naïve: Must not have received any prior systemic anticancer treatment consisting of chemotherapy, immunotherapy, or targeted therapy for unresected stage IIIB to IV melanoma.Xx_NEWLINE_xXSubjects who are currently receiving any other concomitant anticancer therapy with the EXCEPTION of bisphosphonates and hormone therapy.Xx_NEWLINE_xXReceipt of anticancer medications or investigational drugs within the Protocol-defined intervals before the first administration of study drug.Xx_NEWLINE_xXToxicity of ? Grade 2 from prior anticancer therapyXx_NEWLINE_xXThe patient has received treatment with an investigational systemic anticancer agent within 14 days prior to study therapy administration.Xx_NEWLINE_xXSubjects for whom potentially curative anticancer therapy is available.Xx_NEWLINE_xXPatients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of study drug (including chemotherapy, radiation therapy, antibody based therapy, etc.)Xx_NEWLINE_xXIs receiving other concomitant anticancer treatmentXx_NEWLINE_xXTreatment with any systemic anticancer treatment or an investigational agent within 4 weeks and any radiation within 2 weeks of registrationXx_NEWLINE_xXPatients who are receiving any other investigation agents or concurrent anticancer therapy are NOT eligible for participation; previous systemic treatment and/or radiation therapy is allowed with a 14 day washout period prior to registrationXx_NEWLINE_xXConcurrent treatment with any anticancer agent outside of this protocolXx_NEWLINE_xXProgression of disease after the most recent anticancer treatment. At least 1 prior chemotherapy regimen must have included a taxane.Xx_NEWLINE_xXSubject has received chemotherapy, immunotherapy or any other systemic anticancer therapy (including sorafenib) or any other investigational drug within 14 days prior to the Day 1 visit.Xx_NEWLINE_xXThe participant may have had any number of prior systemic cytotoxic therapies for advanced/metastatic disease and are considered appropriate candidates for anthracycline therapy. All previous anticancer treatments must be completed ? 3 weeks (21 days) prior to first dose of study drug.Xx_NEWLINE_xXSignificant unresolved toxicities from previous anticancer therapy that have not resolved, or have not stabilized at a new baselineXx_NEWLINE_xXPatients currently receiving anticancer therapies or who have received anticancer therapies =< 4 weeks prior to registration (including chemotherapy, radiation therapy, antibody based therapy, etc.)Xx_NEWLINE_xXConcurrent use of any other approved or investigational anticancer agents, including hormonal agentsXx_NEWLINE_xXPatients currently receiving anticancer therapies or who have received anticancer therapies within 2 weeks of the start of everolimus (including chemotherapy, radiation therapy, antibody based therapy)Xx_NEWLINE_xXPatients receiving any concurrent anticancer therapy or investigational agents with the intention of treating esophagogastric cancer; last prior therapy must have been completed at least 2 weeks (14 days) prior to starting nintedanibXx_NEWLINE_xXReceipt of anticancer therapy within 28 days prior to the first dose of Investigational ProductXx_NEWLINE_xXUnresolved toxicities from prior anticancer therapyXx_NEWLINE_xXInsufficient recovery from all side effects of previous anticancer therapiesXx_NEWLINE_xXRadiation, chemotherapy, or immunotherapy or any other approved anticancer therapy =< 2 weeks prior to day -7 (beginning of loading phase)Xx_NEWLINE_xXConcurrent therapy with approved or investigational anticancer therapeuticXx_NEWLINE_xXAny investigational agents or other anticancer drugs from a previous treatment regimen or clinical study within 14 days of the first dose of study treatmentXx_NEWLINE_xXPatients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of everolimus and LDE225 (including chemotherapy, radiation therapy, antibody based therapy, etc.)Xx_NEWLINE_xXConcurrent therapy with approved or investigational anticancer therapeuticXx_NEWLINE_xXReceived systemic anticancer therapy or radiation therapy within the previous 14 daysXx_NEWLINE_xXConcurrent anticancer therapy or any cytotoxic therapy within 1 month prior to Day 1. Corticosteroid therapy is not allowed except on dosing days;Xx_NEWLINE_xXSubjects who received systemic anticancer therapy or radiotherapy <21 days prior to their first day of study drug administration.Xx_NEWLINE_xXSubjects for whom potentially curative anticancer therapy is available.Xx_NEWLINE_xXOther concurrent anticancer therapies.Xx_NEWLINE_xXRecovered from toxicities of previous anticancer therapyXx_NEWLINE_xXNo other concurrent anticancer therapies or agentsXx_NEWLINE_xXPrior mifepristone use for anticancer therapy is not allowedXx_NEWLINE_xXSystemic chemotherapy with approved or investigational anticancer therapeutics, including steroid therapy intended to treat underlying malignancy, within 3 weeks before the first dose or 6 weeks for antibody therapyXx_NEWLINE_xXRadiotherapy or systemic therapy (standard or an investigational or biologic anticancer agent) within 14 days of initiation of study drug treatmentXx_NEWLINE_xXPatients who are receiving any other anticancer therapyXx_NEWLINE_xXAnticancer treatment (e.g., radiation therapy, chemotherapy) within 21 days of first dose\r\n* An exception is cetuximab treatment, which can be received within 21 days of the first treatment on study.Xx_NEWLINE_xXPatients currently receiving anticancer therapies or who have received anticancer therapies within 3 weeks of the start of study drug including chemotherapy, biologics, targeted therapies, or immunologicsXx_NEWLINE_xXConcurrent anticancer treatment or concurrent systemic therapy with steroids or other immunosuppressive agents, or use of any investigational drug within 30 days before the start of trial treatment. Short-term administration of steroids (that is, for allergic reactions or the management of immune-related adverse events [irAE]) is allowedXx_NEWLINE_xXAny concurrent anticancer therapy, excluding hormonal therapy for prostate or breast cancerXx_NEWLINE_xXSubjects for whom potentially curative anticancer therapy is available.Xx_NEWLINE_xXAny number and type of prior anticancer therapies except BRAF or mitogen-activated protein kinase (MEK) inhibitorsXx_NEWLINE_xXSubjects may have received up to three prior systemic anticancer treatment regimens for adenocarcinoma of the lung (including adjuvant therapies and tyrosine-kinase inhibitors [TKI]), unless discussed with the sponsor.Xx_NEWLINE_xXSubjects who have received any anticancer therapy (including surgery, locoregional, biological, immunotherapy, hormonal, or radiotherapy) within 21 days before the first dose of study drug (28 days for investigational therapies).Xx_NEWLINE_xXAny cytotoxic chemotherapy, investigational agents or other anticancer drugs from the treatment of advanced NSCLC from a previous treatment regimen or clinical study within 14 days of the first dose of study treatment.Xx_NEWLINE_xXPatients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of study drug (including chemotherapy, radiation therapy, antibody based therapy, etc.)Xx_NEWLINE_xXPatients who are receiving any other investigational agents or concurrent anticancer therapy are NOT eligible for participation; previous systemic treatment is allowed with a 2 week washout period prior to registrationXx_NEWLINE_xXConcurrent treatment with any other anticancer therapyXx_NEWLINE_xXPatients currently receiving anticancer therapies or who have received anticancer therapies within 3 weeks of the start of study drug or patients receiving prior treatment with investigational drugs 4 weeks of the start of study drugXx_NEWLINE_xXConcomitant use of other anticancer (except for corticosteroids) or experimental agentsXx_NEWLINE_xXConcurrent anticancer therapy (including other investigational agents), with the exception of hormone therapy for prostate cancerXx_NEWLINE_xXPatients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of study drug (including chemotherapy, radiation therapy, antibody based therapy, etc.)Xx_NEWLINE_xXSubjects may not be receiving any other standard or investigational anticancer agents, with the exception of hormonal therapyXx_NEWLINE_xXAny anticancer therapy within 3 weeks before study entry; this exclusion does not apply to corticosteroid therapy; the patient must have recovered from all acute toxicities from any previous therapyXx_NEWLINE_xXMust have received at least one prior systemic anticancer therapy for NSCLCXx_NEWLINE_xXPatients with any unresolved toxicity greater than Grade 1 from previous anticancer therapyXx_NEWLINE_xXPatients must have the following minimum wash-out from previous treatments: a) >= 4 weeks for local radiation therapy, systemic cytotoxic anticancer therapy, treatment with other anticancer investigational agents; b) > 2 weeks for oral methotrexate, retinoids or biological response modifiers therapy for any indication, or topical prescription or topical therapy; c) >= 12 weeks for any immunotherapy (e.g., monoclonal antibody); patients with rapidly progressive disease may be treated earlier than the required washout period; patients should have recovered from prior treatment-related toxicitiesXx_NEWLINE_xXConcomitant therapy with any anticancer agents, immunosuppressive agents, other investigational anticancer therapies. Low-dose corticosteroids for the treatment of non cancer-related illnesses are permitted.Xx_NEWLINE_xXNo expectation of further effects of prior anticancer therapyXx_NEWLINE_xXPatients for whom potentially curative anticancer therapy is availableXx_NEWLINE_xXPatients may not be receiving any other experimental agents and/or any other concurrent anticancer agents or therapies except hormonal maintenanceXx_NEWLINE_xXPatients receiving any other anticancer or experimental drug therapyXx_NEWLINE_xXSubjects with RCC (clear cell, non-clear cell histology) with or without prior systemic anticancer therapyXx_NEWLINE_xXExpansion Cohort 1: Subjects with RCC with clear cell histology who have not received prior systemic anticancer therapyXx_NEWLINE_xXAny approved anticancer therapy, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatmentXx_NEWLINE_xXNo prior systemic anticancer therapy (including EGFR and ALK inhibitors)Xx_NEWLINE_xXParticipants who have received any systemic anticancer therapy for RCC, including anti-vascular endothelial growth factor (VEGF) therapy, or any systemic investigational anticancer agentXx_NEWLINE_xXAny type of systemic anticancer therapy (chemotherapy or experimental drugs) within 2 weeks of starting treatment on protocolXx_NEWLINE_xXUse of any other concurrent investigational agents or anticancer agents except for hormonal therapy as outlined in inclusion criteriaXx_NEWLINE_xXFailed to recover from the reversible effects of prior anticancer therapiesXx_NEWLINE_xXCurrently receiving anticancer therapyXx_NEWLINE_xXUse of investigational agents within 30 days or any anticancer therapy for this malignancy within 2 weeks before study entry with the exception of IT therapy, hydroxyurea, or low-dose cytarabine as stated above; the patient must have recovered from all acute toxicities from any previous therapyXx_NEWLINE_xXNo other concurrent anticancer agentsXx_NEWLINE_xXAnticancer chemotherapy or immunotherapy: Anticancer therapy is defined as any agent or combination of agents with clinically proven anticancer activity administered by any route with the purpose of affecting the cancer, either directly or indirectly, including palliative and therapeutic endpointsXx_NEWLINE_xXProgressed or intolerant to at least 1 approved prior anticancer regimen.Xx_NEWLINE_xXSystemic anticancer therapy or major surgery within 28 days prior to registration. In absence of toxicity from prior systemic anticancer therapy, 5 half-lives since completion of prior systemic anticancer therapy is allowed.Xx_NEWLINE_xXOther concurrent anticancer chemotherapyXx_NEWLINE_xXTreatment with other systemic anticancer therapy within 4 weeks prior to the first dose of study medicationXx_NEWLINE_xXPatients may not be receiving any other investigational agent with therapeutic anticancer intentXx_NEWLINE_xXOther concomitant anticancer treatmentXx_NEWLINE_xXPatients who have had anticancer therapy (chemotherapy, immunotherapy, radiotherapy, or investigational therapy) within 2 weeks prior to starting study treatment; hydroxyurea is an exception; administration of hydrea to control high WBC is permittedXx_NEWLINE_xXPatients currently receiving anticancer therapies (including chemotherapy, radiation therapy, antibody based therapy, etc.)Xx_NEWLINE_xXIntervening anticancer treatment subsequent to the EGFR TKI is allowed (but not required).Xx_NEWLINE_xXHas any unresolved toxicity ? Grade 2 from previous anticancer therapyXx_NEWLINE_xXFor Phase l, no more than 3 prior anticancer regimens (IL-2 or interferon do not count towards the total).Xx_NEWLINE_xXAnticancer chemotherapy or immunotherapy during the study or within less than 3 half-lives for anticancer chemotherapy or 6 weeks for antibody therapies (2 weeks for leukemia patients) prior to start of study drug.Xx_NEWLINE_xXSubject has received a monoclonal antibody for anticancer intent within 8 weeks prior to the first dose of study drug.Xx_NEWLINE_xXPatients who are receiving any other investigational agents for anticancer treatment within 3 weeks of starting study medicationXx_NEWLINE_xXConcurrent therapy with approved or investigational anticancer therapeutic other than steroidsXx_NEWLINE_xXPatients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of everolimus (including chemotherapy, radiation therapy, antibody based therapy, etc., but not including somatostatin analogues, e.g., octreotide)Xx_NEWLINE_xXTreatment with anticancer therapy, antibody-based therapy, retinoid therapy, or hormonal therapy within 4 weeks before study drug treatmentXx_NEWLINE_xXConcurrent anticancer therapyXx_NEWLINE_xXConcurrent chronic immunosuppressive or hormone anticancer therapy (except other physiologic hormone replacement)Xx_NEWLINE_xXhave undergone anticancer therapy including chemotherapy (except for hydroxycarbamide at a maximum daily dose of 3000 mg), endocrine therapy, immunotherapy, or the use of other investigational agents within 4 weeks before study entry.Xx_NEWLINE_xXAnticancer treatment with radiation therapy, targeted therapies, chemotherapy, immunotherapy, hormones or other antitumour therapies within 28 days prior to first dose of TH-302.Xx_NEWLINE_xXRECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Patients who are receiving any other anticancer or investigational drug therapyXx_NEWLINE_xXNON-PROGRESSED DIPG (STRATUM 2): Patients who are receiving any other anticancer or investigational drug therapyXx_NEWLINE_xXReceipt of anticancer medications or investigational drugs within a defined interval before the first administration of study drug.Xx_NEWLINE_xXActive or prior documented autoimmune or inflammatory disease within 3 years, with some exceptions 4. Concurrent or prior conventional or investigational anticancer therapy, within 28 days prior to the first dose of study medication(s)Xx_NEWLINE_xXPrior systemic anticancer therapy for metastatic squamous cell lung cancerXx_NEWLINE_xXPreviously treated with 0 to 2 lines of systemic anticancer therapy (cytotoxic or targeted anticancer agents) in the metastatic setting. Hormonal therapy and bone metastases treatment (example, bisphosphonates, denosumab, etc) are not considered forms of systemic anticancer therapy.Xx_NEWLINE_xXReceipt of any conventional or investigational anticancer therapy within 28 days prior to the first dose of MEDI0562.Xx_NEWLINE_xXUnresolved toxicities from prior anticancer therapy.Xx_NEWLINE_xXHistory of prior treatment with at least one line of systemic anticancer therapy, when an approved systemic therapy is available, and no curative option is available for continued treatment.Xx_NEWLINE_xXReceipt of anticancer medications or investigational drugs within the following interval before the first administration of study drug:Xx_NEWLINE_xXRecent therapy with any active anticancer agent within 4 weeks of the 1st dose of the study drugsXx_NEWLINE_xXTreatment with any investigational anticancer drug within 21 days of the first study\n             treatment administrationXx_NEWLINE_xXAdministration of other investigational drugs within 30 days preceding the screening visit, except for anticancer treatments.Xx_NEWLINE_xXSystemic anticancer therapy within 4 weeks of study entry, except for subjects with anaplastic/undifferentiated thyroid cancer who may be enrolled immediately after discontinuation of previous therapyXx_NEWLINE_xXReceipt of any conventional or investigational anticancer treatment within 28 days prior to the first dose of MEDI4276.Xx_NEWLINE_xXConcurrent therapy with approved or investigational anticancer therapeutic other than steroidsXx_NEWLINE_xXPatients receiving systemic anticancer therapy (chemotherapy, “biologics”, immunotherapy) less than 2 weeks prior to starting radiationXx_NEWLINE_xXReceived systemic anticancer therapy or radiotherapy <21 days prior to their first day of study drug administrationXx_NEWLINE_xXSubjects for whom potentially curative anticancer therapy is availableXx_NEWLINE_xXHas received treatment with any systemic anticancer therapy, wide-field radiation, or experimental agent within 4 weeks of receiving cyclophosphamide on Day -3, with the exception of anticancer hormonal therapy, which may not be given within 2 weeks of receiving cyclophosphamide on Day -3. All residual toxicity related to prior anticancer therapies (excluding vitiligo, endocrinopathies on stable replacement therapy, alopecia and Grade 2 fatigue) must resolve to Grade 1 severity or less or return to baseline prior to receipt of study treatment.Xx_NEWLINE_xXApproved anticancer therapy including chemotherapy or immunotherapy.Xx_NEWLINE_xXTreatment with any anticancer therapy or any investigational products within 3 weeks before the first dose of study drug.Xx_NEWLINE_xXPatient has received chemotherapy or anticancer therapy ? 4 weeks prior to starting study drugXx_NEWLINE_xXReceipt of anticancer therapy:Xx_NEWLINE_xXReceipt of any BRAF inhibitor (in metastatic melanoma), or investigational anticancer therapy within 4 weeks prior to the first dose of MEDI0680 (AMP-514)Xx_NEWLINE_xXAny chemotherapy, anticancer antibodies, or other systemic anticancer therapy within 21 days of the first dose of study drugXx_NEWLINE_xXConcurrent treatment with other anticancer therapyXx_NEWLINE_xXSystemic anticancer therapy within 28 daysXx_NEWLINE_xXHave not recovered to ? Grade 1 toxicity from previous anticancer treatments or previous investigational agentsXx_NEWLINE_xXImmunotherapy or chemotherapy with approved or investigational anticancer therapeutics within 21 days of first doseXx_NEWLINE_xXPatients must have completed any prior anticancer treatment and must have recovered from any acute toxicities. The period between the last dose of prior treatment and the first dose of study drug treatment must be at least 1 week for radiotherapy and at least 2 to 3 weeks for all other modalities of therapy including chemotherapy, monoclonal antibody therapy, immunotherapy, other investigational drugs, or other kinase inhibitors.Xx_NEWLINE_xXHas had certain other recent treatment e.g. major surgery, extended field radiation, anticancer therapy, received investigational agent, within the specified time frames prior to study drug administrationXx_NEWLINE_xXAny therapy that is potentially immunosuppressive or has anticancer activity in the 4 weeks prior to device microinjectionXx_NEWLINE_xXAnticancer treatment within 4 weeks of randomization, with the following exceptions:Xx_NEWLINE_xXAnticipated ongoing concomitant anticancer therapy during the study.Xx_NEWLINE_xXHave received chemotherapy, radiation therapy or other anticancer treatment other than crizotinib within 3 weeks prior to the first dose of study drugXx_NEWLINE_xXCurrently receiving anticancer therapy or have received anticancer therapy within the past 28 days or 5 half-lives of the anticancer therapyXx_NEWLINE_xXAnticancer chemotherapy, experimental cancer therapy, or cancer immunotherapy within 4 weeks prior to first dose study drug. Anticancer therapy is defined as any agent or combination of agents with clinically proven anti tumor activity administered by any route with the purpose of affecting the malignancy, either directly or indirectly, including palliative and therapeutic endpoints.Xx_NEWLINE_xXReceipt of other anticancer therapy within 2 - 6 weeks, depending on the treatmentXx_NEWLINE_xXReceipt of anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drug.Xx_NEWLINE_xXConcurrent anticancer treatment with any agent other than iniparib and any co-administered chemotherapeutic agent(s) specified on the parental study protocol are not permitted throughout the course of the study.Xx_NEWLINE_xXPatients currently receiving anticancer therapies or who have received anticancer therapies within 2 weeks of the start of study drug (including chemotherapy, radiation therapy, antibody based therapy, etc.)Xx_NEWLINE_xXReceipt of any investigational anticancer therapy within 4 weeks prior to the first dose of MEDI0639 or in the case of monoclonal antibodies, 6 weeks prior to the first dose of MEDI0639Xx_NEWLINE_xXChemotherapy with approved or investigational anticancer therapeutics within 21 days prior to randomization.Xx_NEWLINE_xXFailed to recover from the reversible effects of prior anticancer therapies;Xx_NEWLINE_xXReceipt of any investigational anticancer therapy within 30 days prior to the first dose of MEDI3617, or in the case of monoclonal antibodies (eg, bevacizumab), 42 days prior to the first dose of MEDI3617Xx_NEWLINE_xXReceiving concurrent treatment with other anticancer therapyXx_NEWLINE_xXConcurrent anticancer therapy (including other investigational agents)Xx_NEWLINE_xXPatients may not be receiving any other investigational agent with therapeutic anticancer intentXx_NEWLINE_xXUse of investigational agents within 30 days or any anticancer therapy within 2 weeks before study entry with the exception of hydroxyurea, low dose cytarabine and intrathecal chemotherapyXx_NEWLINE_xXConcurrently receiving any other concomitant anticancer or experimental drug therapyXx_NEWLINE_xXConcurrent therapy with approved or investigational anticancer therapeutic other than steroidsXx_NEWLINE_xXTreatment with high-dose corticosteroids for anticancer purposes within 7 days before the first dose of TAK-659.Xx_NEWLINE_xXPatients currently receiving any other anticancer therapies;Xx_NEWLINE_xXSystemic anticancer treatment (including investigational agents) or radiotherapy less than 2 weeks before the first dose of study treatment (<=4 weeks for large molecule agents).Xx_NEWLINE_xXPrior anticancer chemotherapy or targeted therapy for advanced nccRCCXx_NEWLINE_xXToxicity from previous anticancer treatment.Xx_NEWLINE_xXRecurrent or progressive malignancy requiring anticancer treatmentXx_NEWLINE_xXStarting a new treatment regimen that includes a single oral anticancer medicationXx_NEWLINE_xXReceipt of any conventional or investigational anticancer therapy within 4 weeks prior to the first dose of durvalumab and IPH2201Xx_NEWLINE_xXAnticancer chemotherapy or immunotherapy during the study or within 4 weeks prior to the first dose of study drugXx_NEWLINE_xXParticipant has received anticancer therapy or any investigational therapy within a period of 21 days prior to the first dose of ABBV-085.Xx_NEWLINE_xXConcurrent therapy with approved or investigational anticancer therapeuticsXx_NEWLINE_xXPatients currently receiving anticancer therapies or who have received anticancer therapies within 4 weeks of the start of everolimus (including chemotherapy, radiation therapy, antibody based therapy, etc)Xx_NEWLINE_xXPatients currently receiving anticancer therapies (except biphosphonate, denosumab);Xx_NEWLINE_xXPatients who have declined further anticancer therapy will be excludedXx_NEWLINE_xXAny cytotoxic chemotherapy, investigational agent or other anticancer drug(s) from a previous cancer treatment regimen or clinical study (other than EGFR TKI), within 14 days of the first dose of study treatmentXx_NEWLINE_xXUse of other anticancer therapy within 15 days before the first dose of M3541 administration and should not be within the \at risk follow-up period\ for that specific anticancer therapy. The use of any investigational agent is not allowed within 28 days before the first dose of M3541Xx_NEWLINE_xXHas progressed after prior therapy and either a) there is no further effective standard anticancer therapy available (including subject refusal) or b) is intolerant to standard anticancer therapy.Xx_NEWLINE_xXTreatment with other investigational study drug for any indication for any reason, or receipt of anticancer medications within 28 days before first dose of study drug; subjects must have recovered from AEs due to previously administered therapies.Xx_NEWLINE_xXHas unresolved toxicities from previous anticancer therapyXx_NEWLINE_xXNo prior exposure to immune-mediated therapy excluding therapeutic anticancer vaccines.Xx_NEWLINE_xXOn any new anticancer therapy (GnRH analog allowed) while on the studyXx_NEWLINE_xXTreatment with anticancer chemotherapy or biologic therapy or with an experimental anticancer agent within 28 days of the initial dose of study drug.Xx_NEWLINE_xXSystemic anticancer treatment (including investigational agents) or radiotherapy less than 2 weeks before the first dose of study treatment (<=4 weeks for large molecule agents; <=8 weeks for cell-based therapy or anti-tumor vaccine), or not recovered from the reversible effects of prior anticancer therapy.Xx_NEWLINE_xXReceipt of anticancer medications or investigational drugs within the protocol-defined intervals before the first administration of study drug.Xx_NEWLINE_xXPrior systemic chemotherapy, small molecule inhibitors, immune checkpoint inhibitors, other monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, T-cell or other cell-based or biologic therapies, or any other anticancer therapy for the treatment of (limited or extensive) SCLC.Xx_NEWLINE_xXConcomitant systemic use of anticancer herbal medications. These should be stopped prior to study entry.Xx_NEWLINE_xXParticipants who have received any anticancer treatment within 21 days or any investigational agent within 30 days (or 5 half-lives) prior to the first dose of study drug and should have recovered from any toxicity related to previous anticancer treatment. This does not apply to the use of TSH suppressive thyroid hormone therapy.Xx_NEWLINE_xXReceipt of anticancer medications or investigational drugs within protocol-defined intervals before the first administration of study drugXx_NEWLINE_xXReceipt of systemic anticancer therapy, including investigational agents, within 28 days of starting study treatment. If anticancer therapy was given within 28 days of starting study treatment, patients may be included if 5 times the elimination half-life of the drug has passedXx_NEWLINE_xXAnticancer chemotherapy, biologics, immunotherapy, radiotherapy, or investigational treatment within 30 days, except for hormone therapy, which could be given up to 7 days prior to the first dose of poziotinib.Xx_NEWLINE_xX